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ABSTRACT 
Breast cancer remains the leading cause of cancer death in women due to 
metastasis and the development of resistance to established therapies. 
Macrophages are the most abundant immune cells in the breast tumor 
microenvironment and can both inhibit and support cancer progression. Thus, 
gaining a better understanding of how macrophages support cancer could lead to the 
development of more effective therapies. In this study, we find that breast cancer 
associated macrophages express high levels of insulin-like growth factors 1 and 2 
(IGFs) and are the main source of IGFs within both primary and metastatic tumors.  
75% of breast cancer patients show activation of Insulin/IGF-1 receptor signaling and 
this correlates with increased macrophage infiltration and advanced tumor stage. In 
patients with invasive breast cancer, activation of Insulin/IGF-1 receptors increased 
to 87%. Blocking IGF in combination with paclitaxel, a chemotherapeutic agent 
commonly used to treat breast cancer, showed a significant reduction in tumor cell 
proliferation and lung metastasis in pre-clinical breast cancer models compared to 
paclitaxel monotherapy. Our findings provide the rationale for further developing the 
combination of paclitaxel with IGF blockers for the treatment of invasive breast 
cancer, and Insulin/IGF1R activation and IGF+ stroma cells as potential biomarker 
candidates for further evaluation. 
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INTRODUCTION  
 
Breast cancer is the leading cause of cancer death in females worldwide, and is 
characterized by a high proliferation rate, an increased capacity to metastasize, and 
its ability to resist standard therapies (1). Triple negative breast cancer (TNBC) is a 
highly metastatic subtype of breast cancer that accounts for approximately 20% of all 
breast cancer cases and has limited efficacious treatment options (2). Current 
standard treatments for metastatic disease include radiotherapy and chemotherapy 
(3, 4). TNBC has a poorer survival rate, its biology is comparatively less well-
understood and currently no effective specific targeted therapy is readily available 
(5). Breast cancer has a propensity to give rise to distant metastasis at sites such as 
the lungs, bone and brain, which can present up to ten years after treatment (6). 
Patients with metastatic breast cancer ultimately often become resistant to current 
chemotherapy treatments and as a result account for >90% of breast cancer deaths 
(7), highlighting the need for new therapeutic targets to treat metastatic burden more 
effectively.  
 
Tumor progression and response to therapy is not only dependent on tumor intrinsic 
mechanisms but also involves modulation by surrounding non-malignant stromal 
cells in the tumor microenvironment (8, 9). Macrophages are  the most abundant 
leukocytes in the breast tumor microenvironment (10) and an increase in tumor 
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associated macrophages (TAMs) correlates with a poorer prognosis in patients (11-
13). Macrophages can be polarized into M1-like anti-tumorigenic macrophages and 
M2-like pro-tumorigenic macrophages (14-16). M2-like macrophages can influence 
tumor initiation, progression, metastasis (17-19) and resistance to therapies (20-22). 
 
Cancer progression relies on the continued propagation of cancer cells which can be 
stimulated by external ligands activating signaling pathways of tumor cell survival 
and proliferation, even when challenged with chemotherapy (23-26). The insulin-like 
growth factor (IGF) signaling axis has been implicated in promoting cancer 
progression in several tumor types including breast cancer (27-29), and in breast 
cancer resistance to estrogen and HER2 receptor inhibition (27, 30-32).Interestingly, 
Fagan et al., showed that tamoxifen resistant ER+ cells showed a reduction in the 
number of IGF-1 receptors while the number of insulin receptors and AKT 
phosphorylation levels remained unaltered when stimulated with Insulin and IGF-2, 
suggesting that both IGF-1 and IGF-2 signaling may support resistance of breast 
cancer cells to therapies (33). However, the role of IGF signaling in tumor 
progression and resistance to chemotherapy in breast cancer is not completely 
understood yet (32). We and others have recently shown that stroma- derived IGFs 
promote survival of cancer cells leading to therapy resistance in pancreatic and brain 
cancer models, respectively (22, 34). In the current studies, we aimed to investigate 
the role of stroma-derived IGF in breast cancer progression and metastasis, and to 
explore the therapeutic opportunity of blocking IGF signaling in combination with 
chemotherapy for the treatment of breast cancer. 
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RESULTS 
Insulin and IGF-1 receptors are activated on tumor cells in biopsies from 
breast cancer patients, and this positively correlates with increased TAM 
infiltration and advanced tumor stage. 
Macrophages play an important role in breast cancer progression and metastasis 
(35, 36) and have been shown to express high levels of IGFs in other cancer types 
(22, 34), but the role of IGF-expressing macrophages in breast cancer has not yet 
been explored. To investigate whether IGF signaling pathways are activated in 
invasive breast cancer progression and whether their activation correlates with 
macrophage infiltration, we first evaluated the activation status of insulin and IGF-1 
receptors in biopsies from breast cancer patients, and the levels of infiltrated tumor 
associated macrophage (TAMs). Immunohistochemical staining of serial sections of 
non-malignant breast tissue (Fig. 1A) and breast cancer patients’ tissues (Fig. 1B 
and C) revealed an increase in phospho-insulin/IGF-1 receptor levels in the breast 
cancer tissues along with increased infiltration of CD68+ (pan-myeloid/macrophage 
marker) and CD163+ (marker commonly used to identify pro-tumorigenic M2-like 
macrophages) macrophages (Fig. 1 A-D). Analysis of a tissue microarray (TMA) 
containing samples from 75 breast cancer patients, with different tumor stages but 
unspecified subtype, showed that Insulin/IGF-1R signaling was activated in 56 of 75 
(~75%) patients (Fig. 1E and Supplementary Table. S1). Activation of insulin/IGF-1 
receptors positively correlates with increased infiltration of CD163+ macrophages in 
the tumor (Fig. 1F) and with advanced tumor stage (Fig.1G).  
87% of patients with invasive breast cancer have Insulin/IGF-1 receptors 
activated. 
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Since Insulin/IGF-1 receptors activation positively correlates with advanced tumor 
stage, we further analysed biopsies from patients with invasive breast cancer.  
Immunohistochemical staining revealed that invasive breast cancer also shows 
increased phospho-insulin/IGF-1 receptor levels in tumor cells surrounded by 
CD163+ macrophages (Fig. 2A). Analysis of a TMA containing 90 samples from 
patients with invasive breast cancer showed that 78 of 90 (~87%) of these patients 
have Insulin/IGF1 receptors activated (Fig. 2B, upper pie diagram, and 
Supplementary Table S2). Among these 90 samples, 51 were TNBC of which 45 
(~88.2%) showed activation of Insulin/IGF1 receptors (Fig. 2B, lower, left pie 
diagram), 13 were hormone receptor positive (HR+) of which 12 (~92%) showed 
activation of Insulin/IGF1 receptors (Fig. 2B, lower, middle pie diagram), and 19 were 
HER2 positive (HER2+) of which 16 (~84%) showed activation of Insulin/IGF1 
receptors (Fig. 2B, lower, right pie diagram). Using the cancer genome atlas 
database we also found that increased gene expression of Igf-1, Igf-2, and the M2-
like macrophage markers cd163 and mrc1 positively correlates with reduced survival 
in breast cancer patients (Fig. 2C). Together these results suggest an important role 
for IGF signaling in invasive breast cancer of all subtypes, including TNBC.  
Tumor associated macrophages and fibroblasts are the main sources of IGF-1 
and IGF-2 in invasive breast cancer. 
To further understand the correlation between activation of Insulin/IGF1 receptors 
and increased TAMs infiltration, we used an orthotopic syngeneic TNBC pre-clinical 
model which has been shown to recapitulate the human disease progression (37). 
Briefly, we isolated murine breast cancer cells (Py230) from the genetically 
engineered spontaneous breast cancer model MMTV-PyMT and transduced isolated 
cells with a reporter lentivirus expressing zsGreen/luciferase allowing in vivo imaging 
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of tumor burden. To induce breast tumor burden, Py230zsGreen/luciferase cells 
were orthotopically implanted into the mammary fat pad of isogenic 
immunocompetent recipient mice.  42 days after implantation, primary tumors were 
surgically removed and tumor tissue sections were analysed by immunofluorescent 
and immunohistochemical staining. We found that tumors were highly infiltrated by 
macrophages (F4/80+, CD68+, CD206+) that surround proliferating tumor cells 
(Ki67+) (Fig. 3A), which also express phosphorylated/activated insulin/IGF-1 
receptors (Fig. 3B). Thus, similar to what we observed in human biopsies, murine 
breast cancer cells, which are spatially located in close proximity to M2-like TAMs, 
have activated Insulin/IGF-1 receptors. 
Next, we aimed to identify the source of insulin and IGF-1 receptors ligands, namely 
IGF-1 and IGF-2, in the tumor microenvironment. Therefore, we enzymatically 
digested primary tumors to prepare single cells suspensions and isolated tumor 
cells, non-immune stromal cells and macrophages, by flow cytometry cell sorting 
(Supplementary Fig.S1A B). Gene expression analysis of isolated cell populations 
revealed that TAMs are the main source  of Igf-1 and that both TAMs and cancer 
associated fibroblasts (CAFs) are major sources of Igf-2 in the breast tumor 
microenvironment (Fig. 3C and D). Immunofluorescent staining of SMA and Ki67 in 
the murine breast tumors showed that SMA+ stromal cells, which appear to be a 
major source of IGF-2, also surround actively dividing tumor cells (Fig. 3E). IGF-1 
and IGF-2 are also expressed in the stroma surrounding cancer cells in human 
TNBC samples (Supplementary Fig. S2A), and gene expression analysis of Igf-1 and 
Igf-2 in human MDA-MB-231 TNBC cells and primary human macrophages revealed 
that human macrophages express high levels of Igf-1 and Igf-2, while there was very 
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little expression of these ligands in the breast cancer cells (Supplementary Fig. S2B 
and C). 
Metastasis associated macrophages and fibroblasts remain the main sources 
of IGF-1 and IGF-2 in pulmonary metastatic lesions.  
Breast cancer is a highly invasive disease and often metastasizes to the lung. 
Orthotopically implanted Py230 breast cancer cells into syngeneic recipient mice 
effectively metastasized to the lung, where they formed metastatic tumors (Fig. 4A). 
We wondered whether IGF-1 and IGF-2 might also be expressed in the metastatic 
tumor microenvironment and thereby provide a survival/proliferative signal to 
disseminated cancer cells. To address this question, we analysed metastatic lung 
tumors from our animal model for the expression of Igf-1 and Igf-2 in the metastasis 
associated stromal cells. 
Metastatic tumors in lungs were first confirmed by bioluminescence ex vivo imaging 
and by hematoxylin and eosin (H&E) staining (Fig. 4A). Immunofluorescent staining 
showed that pulmonary metastatic lesions are surrounded by macrophages (F4/80+) 
and myofibroblasts (SMA+) (Fig. 4B).  Similar to what we observe at the primary 
site, metastasis associated macrophages (MAMs) and fibroblasts express high 
levels of Igf-1 and Igf-2, while disseminated breast cancer cells do not express these 
ligands  (Fig. 4C and D). Together, these findings provide evidence that 
macrophages and fibroblasts are the main sources of IGF-1 and IGF-2 both at the 
primary and the metastatic site in invasive breast cancer. 
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Combination treatment of invasive breast cancer with paclitaxel and IGF 
blocking antibody reduces tumor cell proliferation and metastasis in a 
syngeneic orthotopic Py230-model 
To determine whether IGF signaling affects breast cancer progression, metastasis 
and response to paclitaxel, a standard chemotherapeutic agent used to treat breast 
cancer, we treated mice orthotopically implanted with Py230 TNBC cells, with control 
IgG antibody, IGF-1/2 blocking antibody xentuzumab , paclitaxel or xentuzumab with 
paclitaxel (Fig. 5A). As expected, control and paclitaxel treated mice showed high 
levels of insulin and IGF-1 receptor activation in the primary breast cancer tumors, 
whereas the xentuzumab and xentuzumab with paclitaxel treated groups showed 
markedly reduced levels of insulin and IGF-1 receptor activation, confirming that 
xentuzumab has reached the tumor and has blocked IGF signaling (Fig. 5B) (38). No 
differences were seen in primary tumor growth (Supplementary Fig. S3A), in tumor 
cell death (Supplementary Fig. S3B) or in TAM infiltration of primary tumors 
(Supplementary Fig. S3C) between the different treatment groups. However, control 
IgG treated mice showed higher levels of Ki67+ proliferating tumor cells which were 
modestly reduced by both paclitaxel and xentuzumab single treatments and 
significantly reduced by the combination treatment of xentuzumab with paclitaxel 
(Fig. 5C and D). In addition, mice treated with the combination of xentuzumab with 
paclitaxel treatment showed a reduction in lung metastasis incidence (Fig. 5E). 
Although there were no significant differences in the number of metastatic foci in the 
different treatment groups (Fig. 5F), we found a significant reduction in the size of 
metastatic lesions and overall lung metastatic burden in the group treated with both 
paclitaxel and xentuzumab (Fig. 5G, H and I). These data suggest that initial 
metastatic seeding is not affected by the combination treatment, but that 
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paclitaxel/xentuzumab treatment impairs metastatic outgrowth of disseminated 
breast cancer cells. 
 
Combination treatment of invasive breast cancer with paclitaxel and IGF 
blocking antibody reduces tumor cell proliferation and metastasis in a 
syngeneic orthotopic 4T1 model 
To confirm the results from the Py230 experiment in another model, 4T1-
zsGreen/luciferase cells were implanted into the mammary fatpad of syngeneic 
Balb/c mice and treated with isotype control antibody, paclitaxel, xentuzumab or 
paclitaxel with xentuzumab (Fig. 6A). In accordance with our previous findings, 
insulin and IGF-1R receptor activation was markedly reduced in the mice treated 
with xentuzumab alone and paclitaxel with xentuzumab (Supplementary Fig. S4A) 
(38). In this model, we found that primary tumor growth was significantly reduced by 
paclitaxel treatment and even further reduced by the combination treatment 
paclitaxel + xentuzumab (Fig. 6B). Analysis of Ki67+ proliferating cells in the primary 
tumor showed a significant reduction in paclitaxel treated mice and reduced further in 
paclitaxel with xentuzumab treated mice compared to control IgG mice (Fig. 6C and 
D). The numbers of lung metastatic foci were significantly reduced by both paclitaxel 
alone and the combination of paclitaxel + xentuzumab compared to control treatment 
group (Fig. 6E). However, only the combination treatment of paclitaxel + xentuzumab 
significantly reduced the average metastatic lesion size and the overall metastatic 
burden (Fig. 6F, G and H).  
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Taken together, our findings indicate that IGF-1 and 2 are highly expressed by both 
macrophages and fibroblasts in invasive breast cancer, and that blockade of IGF 
potentiates the efficacy of paclitaxel (Fig. 6I).  
 
DISCUSSION  
Here we show that IGF-1 and 2 are secreted by macrophages and fibroblasts, both 
at the primary site and metastatic site in invasive breast cancer, and that blocking 
IGF increases the efficacy of paclitaxel, a chemotherapeutic agent commonly used 
for the treatment of invasive breast cancer (Fig. 6I). Breast cancer, and in particular 
TNBC, remains a highly metastatic and potentially lethal disease with a need to 
identify additional specific molecular targets and to develop more effective therapies 
(4, 5). While IGF signaling has been shown to support progression of HR+ and 
HER2+ breast cancer and the development of resistance to established therapies, its 
precise role in TNBC remains elusive (32). In our TNBC model, we found that TAMs 
and CAFs secrete IGF-1 and 2 at both the primary site and the pulmonary metastatic 
site. Zhang et al., previously reported that CAF-derived IGF-1 primes breast cancer 
cells for bone metastasis (39). These studies both suggest that stromal-derived IGF 
plays an important role in the metastatic process of breast cancer. 
In this study, we find that the Insulin/IGF1R signaling pathway is activated in 78 of 90 
(~87%) of patients with invasive breast cancer and in 45 of 51 (~88.2%) TNBC 
patients, suggesting IGF may be a promising therapeutic target for this highly 
aggressive breast cancer subtype. We also observed that activation of Insulin/IGF1 
receptor signaling positively correlates with increased levels of macrophage 
infiltration and advanced tumor stage in patients, suggesting that Insulin/IGF1 
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receptor activation and/or stroma expression of IGF could be predictive biomarker 
candidates for further evaluation.  
To investigate the therapeutic potential of blocking IGF signaling in invasive breast 
cancer, we tested the IGF-1/2 blocking antibody xentuzumab (Boehringer Ingelheim) 
in two pre-clinical mouse models of invasive TNBC breast cancer which metastasize 
to the lungs. In both models, we find that combining xentuzumab with paclitaxel 
results in reduced incidence of metastasis, as well as a significant reduction of 
tumour cell proliferation and metastatic burden compared to monotherapy. In 
agreement with our findings, Gooch et al., previously showed that IGF-1 promotes 
proliferation of paclitaxel treated cells in vitro (40). Interestingly, xentuzumab + 
paclitaxel combination treatment significantly decreases the size of metastatic 
lesions but not the number of foci suggesting that the combination treatment affects 
metastatic outgrowth rather than the metastatic seeding. 
IGF1R inhibitors have been assessed in clinical trials for metastatic hormone 
receptor positive (HR+) as well as triple negative breast cancer but have shown 
limited success (41-46). Two promising IGF ligand blocking antibodies, xentuzumab 
and MEDI-573, are currently being evaluated in clinical trials in HR+ metastatic 
breast cancer patients in combination with everolimus and exemestane 
(NCT02123823) and in hormone sensitive metastatic breast cancer in combination 
with letrozole (NCT01446159) respectively.  In contrast to IGF1R antibodies, IGF 
blocking antibodies neutralize both ligands IGF-1 and IGF-2 and thereby inhibit 
proliferative signaling through both Insulin and IGF1 receptors without affecting 
insulin metabolic signaling (38, 47).         
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Breast cancer cells survive poorly in isolation and participate in a complex 
relationship with surrounding stromal and immune cells in the tumor 
microenvironment which can support tumor cell survival, proliferation and spreading 
to other organs (17, 20, 21, 36, 39). CAFs and TAMs are the most abundant stromal 
cells in solid cancers, including breast cancer. However, different populations of 
CAFs and TAMs with both pro- and anti-tumorigenic functions co-exist in tumors (48-
50). Therefore, therapies aiming to specifically inhibit the tumor supporting functions 
of stromal cells, without affecting their anti-tumorigenic functions, may be more 
effective than ablation therapies in restraining tumor progression (26, 51). Our 
findings indicate that blocking IGFs in combination with paclitaxel, decreases tumor 
cell proliferation and breast cancer pulmonary metastasis without affecting 
macrophage infiltration. In conclusion, this study suggests that stroma-derived IGFs 
support breast cancer metastasis and modulate its response to paclitaxel, providing 
the rationale for further evaluation of IGF blocking antibodies in combination with 
paclitaxel in the treatment of invasive breast cancer.   
 
Materials and Methods  
Generation of primary PyMT-derived breast cancer cells 
Py230 cells (hormone receptor negative and HER2 low) were generated in Ellies lab 
(University of California San Diego, U.S.A) and obtained from spontaneously arising 
tumors in MMTV-PyMT C57Bl/6 female mice by serial trypsinization and limiting 
dilution (52). The mouse model used for obtaining these tumors has been described 
in detail previously (53, 54).  
 
14 
 
Generation of 4T1 derived breast cancer cells 
4T1 cells were purchased from the ATCC and were originally obtained from a 
spontaneously arising mammary tumor in BALB/cfC3H mice (55, 56). The orthotopic 
model using these cells has been described in detail previously (57). 
Cell lines and culture conditions 
Murine Py230 cells were cultured in DMEM/F-12 culture media supplemented with 
10% FBS and supplemented with MITO serum extender (Corning #355006), 1% 
penicillin/streptomycin at 37°C, in a 5% CO2 incubator. Murine 4T1 cells were 
cultured in RPMI-1640 culture media supplemented with 10% FBS, 1% 
penicillin/streptomycin at 37°C, in a 5% CO2 incubator. Human MDA-MB231 breast 
cancer cells were cultured in DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin, at 37°C, 5% CO2 incubator. Cells were authenticated, and 
periodically tested for mycoplasma contamination. 
Generation of primary macrophages 
Primary human macrophages were obtained from blood samples of healthy 
volunteers. Magnetic bead affinity chromatography was performed to purify CD14+ 
monocytes as per manufacturer’s instructions (Miltenyi Biotec, Woking, UK). 
Monocytes were incubated in RPMI media with 10% FBS and 50 ng/mL recombinant 
human M-CSF (Peprotech, London, UK) for 5 days post-purification. 
Syngeneic orthotopic breast cancer models 
Two orthotopic syngeneic breast cancer models were used in these studies. In the 
first breast cancer model (Figure 5), 2 x106 Py230 luciferase/zsGreen labelled cells 
were injected into the fat pad of the third mammary gland of C57BL/6 6-8 week-old 
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female mice. In the second model (Figure 6), 5x105 4T1 luciferase/zsGreen labelled 
cells were injected into the fat pad of the third mammary gland of BALB/c 6-8 week 
old female mice. Tumors were measured with calipers twice a week and treatment 
was started when tumors started to grow and measured between 5-8mm mean 
diameter. Mice were administered i.p with IgG isotype control antibody, paclitaxel 
(100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) (38) kindly 
provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab , twice a week for 
15 days. At humane endpoint, primary tumors and lungs were harvested, imaged 
using IVIS technology and tissues were either digested for FACS sorting and 
analysis (see details below) or formalin fixed and paraffin embedded. Paraffin 
embedded lungs were serially sectioned through the entire lung. Sections were 
stained with hematoxylin and eosin (H&E), and images were taken using a Zeiss 
Observer Z1 Microscope. Number of foci and total area of metastatic foci were 
calculated to estimate seeding and metastasis burden using ZEN imaging software.  
FACS sorting and analysis of tumors 
Tumor cells, tumor associated macrophages and stromal cells from murine primary 
breast tumors and pulmonary metastasis were analysed and sorted using flow 
cytometry (FACS ARIA II, BD Bioscience, CA, USA). Single cell suspensions were 
prepared as previously described (22).  Cells were stained with Sytox® blue viability 
marker (Life Technologies, Warrington, UK) and conjugated antibodies against anti-
CD45-PE/Cy7 (Biolegend, Cambridge, UK, clone 30-F11) and anti-F4/80-APC 
(Biolegend, clone BM8) and analysed using FACS Canto II (BD Biosciences). 
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Gene expression 
Total RNA was isolated from FACS sorted tumor cells, tumor associated 
macrophages and stromal cells from primary breast tumors and lung metastasis. 
RNA extraction and cDNA were performed as previously described (22). Gene 
specific Qiagen QuantiTect Assay primers were used for qPCR analysis and relative 
expression levels were normalized to gapdh expression using the formula <2^− (Ct 
gene of interest – Ct gapdh) (58). 
Gene expression analysis in TCGA database. 
We analyzed the Cancer Genome Atlas (TCGA) data for association between gene 
expression levels of Igf1, Igf2, cd163 and mrc1 and 5-year overall survival. The 
R/Bioconductor package 'TCGA2STAT' (v1.2) (59) was used to download the 
Illumina HiSeq RNAseqV2 mRNA expression and clinical data for 1097 Breast 
cancer samples from the TCGA data portal. The clinical data set was filtered down to 
contain only those breast cancer cases classified as "infiltrating/invasive ductal 
carcinoma", resulting in a reduced data set of 879 patients. For each of the 
candidate genes, we assessed two groups of patients; one consisting of those 
expressing the gene in the top 10% of expression and another containing patients 
expressing the gene in the bottom 10%. We compared their survival using a log rank 
test at 5% significance, using the ‘survival’ (v2.41-3) package and plotted Kaplan-
Meier curves for our ‘high’ and ‘low’ gene expression groups using ‘survminer’ 
(v0.4.0) within the 'TCGAbrowser' (v0.1.0) toolkit, reporting the p value from the log-
rank test (see Figure 2C). 
 
 
17 
 
Tissue Microarrays 
A tissue microarray (TMA) containing 75 breast cancer samples from consented 
patients was purchased from the Liverpool Tissue Bank. This TMA did not provide 
information of cancer subtypes. A second tissue microarray BR10011 containing 90 
invasive breast cancer samples was purchased from U.S Biomax. Among these 90 
invasive breast cancer samples 51 were TNBC, 13 were hormone receptor positive 
(HR+) and 19 were HER2+ .Both TMAs were subjected to immunohistochemical 
staining and scoring by a pathologist.  Detailed information of both TMAs is provided 
in Supplementary Tables S1 and S2. 
Immunohistochemistry and Immunofluorescence 
An automated DAKO PT-link (DAKO, Ely, UK) was used for deparaffinization and 
antigen retrieval of paraffin-embedded human and mouse breast tumors and lung 
metastasis.  Tissues were immuno-stained using the DAKO envision+ system-HRP.   
Antibodies and procedure used for Immunohistochemistry: 
All primary antibodies were incubated for 2 hours at room temperature diluted in 
DAKO envision kit antibody diluent: Mouse CD68 (Abcam, Cambridge, UK, ab31630 
used at 1:100 after low pH retrieval). Human CD68 (DAKO, clone KP1, M081401-2), 
CD163 (Abcam, ab74604), Phospho Insulin/IGF-1R (R&D, Abingdon, UK, AF2507), 
phospho Insulin receptor (Lifespan Biosciences, Nottingham, UK, LS-C177981), 
phospho-IGF-1R (Biorbyt, Cambridge, UK, orb97626), IGF-1 (Abcam, ab9572), IGF-
2 (Abcam, ab9574), CD206 (Abcam, ab8918), dilutions and conditions used as 
previously described (22).  Subsequently, samples were incubated with secondary 
HRP-conjugated antibody (from DAKO envision kit) for 1 hour at room temperature. 
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Staining was developed using diamino-benzidine and counterstained with 
hematoxylin.   
Antibodies and procedure used for Immunofluorescence on paraffin embedded 
tissues: 
Tissue sections were incubated overnight at RT with the following primary antibodies 
F4/80 (Biolegend, #123102 used at 1:200 after low pH antigen retrieval), Ki67 
(Abcam ab15580 used at 1:1000 after low pH antigen retrieval) SMA (Abcam 
ab7817 used at 1:100, after low pH antigen retrieval). Samples were washed with 
PBS and incubated with goat anti-rat 488 (Abcam ab96887), goat anti-rabbit 594 
(Abcam ab98473) and goat anti mouse 488 (Abcam ab98637) secondary antibodies 
respectively all used at 1:300 and DAPI  at 1:600 for 2 hours at RT. Slides were 
washed with PBS, final quick wash with distilled water and mounted using DAKO 
fluorescent mounting media.  
Statistical Methods 
Statistical analysis for in vitro assays and animal studies was performed using 
unpaired two-tailed Student t test or one-way ANOVA coupled with Bonferroni’s post 
hoc tests, and the GraphPad Prism 5 program. All error bars indicate SD of n=3 (in 
vitro studies) or SEM n=3-9 (animal studies). Human samples were analyzed using 
Fisher’s exact test and the Matlab version 2006b program. For animal studies the 
group size was calculated by power analysis using a significance level kept at 5% 
and the power at 80% (according to approved corresponding Home Office Project 
License Application). 
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Institutional approvals 
Human tissue studies adhered to national guidelines and were approved by the 
University of Liverpool. Human breast cancer tissues were either patient-consented 
excess material obtained from the Liverpool Tissue Bank or purchased from U.S 
Biomax. Mice were maintained under specific pathogen-free conditions and 
experiments were performed under an approved project licence (reference number: 
403725) as according to current UK legislation, at the Biomedical Science Unit at the 
University of Liverpool. Blood collection studies were approved by the National 
Research Ethics (Research Integrity and Governance Ethics committee- Reference: 
RETH000807). Informed consent for blood donation was given from each volunteer 
based on approved institutional protocols. 
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Figure legends 
Figure 1. 75% of breast cancer patients have activated Insulin/IGF1 receptors 
and Insulin/IGF-1 receptor activation positively correlates with macrophage 
infiltration and advanced tumor stage. 
(A) Serial sections of biopsies from non-malignant breast tissue immunohistochemically 
stained for phospho-Insulin/IGF1 receptor, CD163 and CD68. Scale bars, 100 m and 50 
m. (B) and (C) Serial sections of biopsies from breast cancer patients 
immunohistochemically stained for phospho-Insulin/IGF1 receptor, CD163 and CD68. Scale 
bars, 100 m and 50 m. (D) Bar graph depicting the quantification of CD68 and CD163 
positive macrophages in non-malignant breast tissue and breast cancer tissue samples. 
Error bars represent s.d. (n=3); * two tailed p value ≤ 0.05, *** two tailed p value ≤ 0.005 
using a student’s t- test. (E) Pie diagram representing the percentage of phospho-
Insulin/IGF-1 receptor positive (red) and negative (green) tumors assessed in a tissue 
microarray containing biopsies from 75 breast cancer patients. (F) Contingency table and 
results from statistical analysis showing a positive correlation between phospho-Insulin/IGF-
1 receptor expression in breast tumors and increased CD163+ macrophage infiltration. Chi-
square = 4.37; p= 0.04. (G) Contingency table and results from statistical analysis showing a 
positive correlation between phospho-Insulin/IGF1 receptor and CD163+ macrophages co-
expression and tumor stage. Chi-square =4.89; p=0.03.  
Figure 2. 87% of patients with invasive breast cancer have activated 
Insulin/IGF1 receptors. 
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(A) Immunohistochemical staining of invasive breast cancer tissue serial sections stained for 
phospho-Insulin/IGF1 receptor and CD163. Scale bars, 100 μm and 50 μm. (B) Upper 
diagram: Pie diagram representing the percentage of phospho-Insulin/IGF1 receptor positive 
(red) and negative (green) tumors assessed in tissue microarray (TMA) containing biopsies 
from 90 consented patients with invasive breast cancer. Lower diagrams: represent the 
percentage of phospho-Insulin/IGF1 receptor positive (red) and negative (green) tumors of 
the molecular subsets, TNBC, HR+ and HER2+. (C) Expression levels of Igf-1, Igf-2, cd163 
and mrc1 associated with survival in breast cancer patients.   
Figure 3. TAMs and CAFs are the main sources of IGF-1 and IGF-2 in invasive 
breast adenocarcinomas. 
(A) PY230 tumor cells were subcutaneously implanted into the third mammary gland of 
syngeneic recipient mice. Images show immunofluorescent staining for F4/80 (green), Ki67 
(red) and nuclei (blue) in murine breast cancer tissue harvested at day 42 after tumor 
implantation. Scale bar 50 μm. (B) Serial sections of immunohistochemical staining for 
CD68, CD206 and phospho-Insulin/IGF1 receptor in murine breast tumors. Scale bar 50 μm. 
(C)  Igf-1 mRNA expression levels were quantified in tumor cells, non-immune stromal cells 
and tumor associated macrophages isolated from murine breast cancer tumors by flow 
cytometry. Error bars represent s.e. (n=3), * p value ≤ 0.05 using one-way ANOVA and 
Bonferroni post-hoc test. (D) Igf-2 mRNA expression levels were quantified in tumor cells, 
non-immune stromal cells and tumor associated macrophages isolated from murine breast 
cancer tumors by flow cytometry. Error bars represent s.e. (n=3), * p value ≤ 0.05 using one-
way ANOVA and Bonferroni post-hoc test. (E) Immunofluorescent images of αSMA (green), 
Ki67 (red) and nuclei (blue) in breast tumors. Scale bar 50 μm.  
Figure 4. Metastasis associated macrophages and fibroblasts express IGF-1 
and IGF-2 in metastatic lungs. 
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 (A) Left, identification of metastatic tumor lesions in the lung by bioluminescent imaging 
technique of orthotopically implanted PY230luc breast cancer cells. Right, images show H&E 
staining of metastatic foci in the lungs. Arrows indicate metastatic foci, scale bars 200 μm, 
100μm and 50 μm. (B) Immunofluorescent images of lung metastatic foci stained for F4/80 
(green), SMA (green), Ki67 (red) and nuclei (blue). Scale bar 50 μm. (C) Quantification of 
Igf-1 mRNA expression levels in metastatic tumor cells, metastasis associated non-immune 
stromal cells and metastasis associated macrophages isolated from pulmonary metastasis. 
Error bars represent s.e. (n=3), * p value ≤ 0.05, *** p value ≤ 0.0001 using one-way ANOVA 
and Bonferroni post-hoc test. (D) Quantification of Igf-2 mRNA expression levels in 
metastatic tumor cells, metastasis associated non-immune stromal cells and metastasis 
associated macrophages isolated from pulmonary metastasis. Error bars represent s.e. 
(n=3), ***p value ≤ 0.05 using one-way ANOVA and Bonferroni post-hoc test. 
 
Figure 5. Combined treatment of IGF blocking antibody with paclitaxel 
decreases breast cancer proliferation and metastasis in Py230 model. 
(A) Py230-luciferase cells were orthotopically implanted into the third mammary fatpad of 
syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached 
between 5-8mm2, twice a week i.p., with control IgG antibody, IGF blocking antibody 
xentuzumab (100mg/kg), paclitaxel (100mg/kg) or a combination of xentuzumab with 
paclitaxel (n= 8 mice/group). (B) Immunohistochemical staining of phospho-insulin/IGF-1R in 
breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 
Scale bars 100 μm and 50 μm. (C) Immunofluorescent staining of Ki67 in primary tumors 
treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bar 50 
μm. (D)  Quantification of Ki67 positive tumor cells in tumors treated with IgG (control), 
paclitaxel, xentuzumab or paclitaxel + xentuzumab.  3-5 fields counted/ mouse tumor, n=3-4 
mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post-hoc test.  
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(E) Percentage of mice presenting with lung metastasis per treatment group. (n=8 mice 
/group). (F) Quantification of number of lung metastatic foci per 100mm2 in mice treated with 
control IgG, paclitaxel, xentuzumab or paclitaxel + xentuzumab. ns, non-significant 
differences using one-way ANOVA and Bonferroni post-hoc test. (G) Average size of 
pulmonary metastatic lesions (mm2) in mice treated with control IgG, paclitaxel, xentuzumab 
or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post-hoc test. 
(H) H&E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, 
xentuzumab or paclitaxel + xentuzumab. Scale bar 50 μm. (I) Total metastatic burden (mm2) 
in mice treated with control IgG, paclitaxel, xentuzumab and paclitaxel with xentuzumab, * p 
≤ 0.05, using one-way ANOVA and Bonferroni post-hoc test.  
Figure 6. Combined IGF blocking antibody with paclitaxel decreases 
metastatic burden in 4T1 breast cancer model  
(A) 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary 
fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached 
approximately 5mm mean diameter, over two weeks the mice received 4 treatments by i.p. 
with control human IgG antibody (n=8 mice), IGF blocking antibody xentuzumab (100mg/kg) 
(n=8 mice), paclitaxel (100mg/kg) (n=9 mice) or a combination of xentuzumab with paclitaxel 
(n= 9 mice). (B) Graph showing tumor mean diameter (mm2) measured by calipers before 
and during treatment with isotype control, xentuzumab, paclitaxel and paclitaxel with 
xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n=8, paclitaxel and 
paclitaxel with xentuzumab n=9), * p value ≤ 0.05, ** p value ≤ 0.01 using two-way ANOVA 
and Bonferroni post-hoc test. (C) Immunofluorescent staining of Ki67 in primary tumors 
treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bar 50 
μm. (D) Quantification of Ki67 positive tumor cells in tumors treated with human IgG 
(control), paclitaxel, xentuzumab or paclitaxel + xentuzumab.  3-5 fields counted/ mouse 
tumor, n=8-9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 
32 
 
0.0001 p using one-way ANOVA and Bonferroni post-hoc test. Images quantified using NIS-
Elements Advanced Research software. (E) Quantification of number of lung metastatic foci 
per 100mm2 in mice treated with control IgG, paclitaxel, xentuzumab or paclitaxel + 
xentuzumab. Error bars represent s.e. (IgG antibody n=7, paclitaxel n=9, xentuzumab n=8, 
and paclitaxel with xentuzumab n=9) ns, non-significant differences, * p value ≤ 0.05, using 
one-way ANOVA and Bonferroni post-hoc test. (F) Average size of pulmonary metastatic 
lesions (mm2) in mice treated with control IgG, paclitaxel, xentuzumab or paclitaxel + 
xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using 
one-way ANOVA and Bonferroni post-hoc test. (G) H&E staining of lung metastatic foci in 
mice treated with control IgG, paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bar 
50 μm. (H) Total metastatic burden (mm2) in mice treated with control IgG, paclitaxel, 
xentuzumab and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant 
differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post-hoc test. (I) Schematics 
describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic 
breast cancer to paclitaxel. 
 
 
